This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Jotrol overcomes these barriers using patented micellar technology, enhancing bioavailability and enabling therapeutically effective doses. Conventional resveratrol products often face challenges like poor absorption and significant gastrointestinal side effects.
The stable gel matrix holds multiple ingredients, offering targeted release and enhanced bioavailability while optimizing patient experience. Gelteq centers its technology on a proprietary, customizable gel platform designed for precise drug delivery, supporting prescription drugs, nutraceuticals, pet care and sports supplements.
Clinical-stage biotech company PureTech Health has announced it has developed a new oral CBD therapeutic candidate with improved bioavailability and tolerability, which could expand use of the CBD prodrug in a wide range of indications and age groups.
The HALO platform enhances peptide half-life, facilitating monthly dosing and titration-free regimens, while the MOMENTUM platform optimizes oral bioavailability. Metseras HALO platform and MOMENTUM oral peptide delivery platform were used to develop these candidates. billion in 2024 to $37.94
Improved bioavailability can lead to a faster onset of therapeutic effects, which is especially valuable in conditions where prompt action is required. Advanced formulation techniques are often required to improve the solubility and bioavailability of these APIs. Dosing flexibility is another prominent advantage provided by PDFs.
Therefore, techniques and technologies that promote drug solubility and bioavailability are in high demand. Their focus is on improving drug solubility and bioavailability with powerful amorphous dispersion technologies, such as KinetiSol for poorly soluble compounds.
NEO:CYBN ) (“ Cybin ”), a lifesciences company focused on psychedelic pharmaceutical therapies, announces the unaudited financial results of Clarmin Explorations Inc. Cybin is a lifesciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. 30, 2020 01:00 UTC.
For healthcare and lifesciences industries, Skin Cancer Awareness Month helps highlight the importance of preventive measures and early detection. is a biotech and lifesciences company dedicated to advancing the clinical development of innovative and groundbreaking therapeutic assets.
By avoiding the stomach entirely, there is increased bioavailability and more sustained relief from symptoms. Switching to an infusion can overcome the disadvantages of the oral treatment, such as low gastrointestinal absorption and narrow therapeutic window.
Unlike fulvestrant, elacestrant is not only orally bioavailable, but it has also demonstrated longer steady-states and works as a better combination partner with inhibitor agents like CDK4/6. Elacestrant had previously shown significant anti-estrogenic activity and potent anti-tumor activity in xenograft models.
Furthermore, the bioavailability of the active pharmaceutical ingredient (API) into the cornea is up to four times stronger with EyeSol technology. This innovative approach signifies a significant milestone in addressing the limitations of conventional eye care therapies.
With positive outcomes in preclinical models, EB-003 has confirmed oral bioavailability, adding to its therapeutic potential. Enveric is set to file an Investigational New Drug (IND) application by the third quarter of 2025, with plans to start clinical development by the end of the year.
Despite their potential, oligonucleotides present challenges in bioavailability due to their large, hydrophobic and negatively charged nature. Oligonucleotides such as antisense and small-interfering RNAs, are crafted using advanced chemical processes. They act by modifying protein expression, offering new treatments for rare diseases.
A major obstacle for CNS drug developers is the inability to target therapies to the CNS broadly (for instance, a therapy that is orally bioavailable as a pill and has difficulty crossing the blood-brain barrier) and certain CNS regions more specifically. The patients are waiting! Modern-Day Applications of Direct CNS Administration.
They are exploring a prodrug formulation of ganaxolone to potentially enhance the patient experience and treatment effectiveness by aiming to improve the drug’s bioavailability. This pursuit of improvement leads Marinus to investigate various aspects of ganaxolone’s potential.
It was engineered to have high potency, bioavailability and kinase selectivity that led to improved efficacy and safety in B-cell malignancies. Zanubrutinib was specifically designed to improve outcomes and be successful where first- and second-generation BTK inhibitors were not.
As a bioscience accelerator at the leading-edge of the lifescience industry, XPhyto targets growth through commercialization of its product pipeline and focused investment in impact driven innovation with the potential for meaningful value creation. .
VANCOUVER, BC / ACCESSWIRE / January 28, 2021 / XPhyto Therapeutics Corp.
She holds a bachelor’s degree in pharmaceutical sciences from a prestigious institute, which has provided her with a strong academic background. With her commitment to staying at the forefront of the healthcare and lifesciences domain, she is able to effectively analyze complex datasets and provide actionable insights.
Without effective disease-modifying therapies and optimal management strategies, the constant fatigue, swelling and mental health challenges surrounding those living with C3G profoundly disrupt daily life and overall quality of life.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content